Annual report
4503.TEDINET S100TNPZ
Period2023-04-01 → 2024-03-31
Filed2024-06-20
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.60T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥1.52T | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥1.30T | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.25T | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.30T | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥25.5bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥133.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥25.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥132.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥156.9bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥145.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥245.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥17.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥98.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥124.1bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥120.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥195.4bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥17.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥98.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥3.57T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥2.46T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥2.33T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.27T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.32T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.97T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥948.6bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.60T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.51T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.46T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.60T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.51T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.46T | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.39T | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.29T | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥335.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥376.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥316.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥326.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥318.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥172.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥327.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥257.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥306.8bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥222.0bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥845.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥84.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥62.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥81.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥389.8bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥614.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥195.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥216.3bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥229.5bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥181.1bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥9.51 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥54.24 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥67.08 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥64.93 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥104.15 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥9.47 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥54.09 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥67.05 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥64.9 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥104.08 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥890.07 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥839.26 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥799.26 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥748.03 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥694.03 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 44.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.0% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 55.7% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 1.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.7% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.7% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 9.0% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 15.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 14,754 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 14,484 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 14,522 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 15,455 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 15,883 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥688.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥613.6bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥542.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥545.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥600.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥194.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥130.6bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥373.3bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥338.2bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥270.5bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥223.4bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥293.2bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥333.1bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥348.1bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥292.2bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥314.2bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥225.1bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥193.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥240.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.46T | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥1.49T | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥1.39T | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.35T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.33T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.28T | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥466.1bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.18T | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.02T | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥873.6bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥787.7bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥671.6bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥153.1bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥217.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥162.92 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.64 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥121.69 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.95 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥128.26 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥162.87 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥172.57 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥121.63 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥103.89 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥128.17 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥70 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥42 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥660 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥568.97 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥477.81 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥424.69 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥361.08 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 48.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 26.5% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 33.2% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 27.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 26.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 39.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,809,663,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,809,663,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,835,852,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,861,787,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,861,787,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,806 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 4,867 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3,943 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 4,647 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 4,560 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceuticalreportable segment | employees | at 2024-03-31 | 14754 pure |
| Pharmaceuticalreportable segment | employees | at 2024-03-31 | 4806 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,686
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)EY新日本有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)古 杉 裕 亮 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)小 山 晃 平 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)今 野 光 晴 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)IVERIC bio, Inc. の企業結合に伴い取得した無形資産 (仕掛研究開発) の取得日時点の公正価値の測定 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)「注記４ 重要な会計上の見積り、判断及び仮定」、「注記17 無形資産」、「注記34 企業結合」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)新薬開発に関して無形資産として計上されている仕掛研究開発の減損要否 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)「注記３ 重要性がある会計方針」及び「注記17 無形資産」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row3Member | Original text (Japanese)返金負債として計上されている米国におけるメディケイド、メディケア及びマネージドケアプログラムに関するリベートの見積り | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row3Member | Original text (Japanese)「注記27 その他の負債」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)EY新日本有限責任監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)古 杉 裕 亮 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)小 山 晃 平 | |
| Cpa3 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)今 野 光 晴 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)繰延税金資産の回収可能性に関する判断 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)【注記事項】 (重要な会計上の見積り) 及び (税効果会計関係) | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Revenue IFRS (5-year summary) | Prior4YearDuration | 1300843000000 | JPY |
| Revenue IFRS (5-year summary) | Prior3YearDuration | 1249528000000 | JPY |
| Revenue IFRS (5-year summary) | Prior2YearDuration | 1296163000000 | JPY |
| Revenue IFRS (5-year summary) | Prior1YearDuration | 1518619000000 | JPY |
| Revenue IFRS (5-year summary) | CurrentYearDuration | 1603672000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior4YearDuration | 245350000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior3YearDuration | 145324000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior2YearDuration | 156886000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YearDuration | 132361000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | CurrentYearDuration | 24969000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior4YearDuration | 195411000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior3YearDuration | 120589000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior2YearDuration | 124086000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | 98714000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | CurrentYearDuration | 17045000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |